Monthly Archives: February 2023

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

— First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway inAustralia — — Company has transitioned from a discovery to a development organization – — Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 — –   Vancouver, British Columbia, February 27, 2023 – Bright Minds…

Bright Minds Biosciences Announces Non-Executive Director Appointment

— David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare diseases —   Vancouver, British Columbia, February 17, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of…

Bright Minds Bioscienes Announces Receipt of NASDAQ Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Vancouver, British Columbia, February 8, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a letter (the “Deficiency Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated February 2, 2023, stating that following the resignation of Dr. Williamson from the Company’s board of directors and audit…